Arcus Biosciences RCUS
NYSE RCUS
$20.58 -3.17 (-13.33%)
As of: Oct 21, 2026 · 1:16 PM EDT

Arcus Biosciences (RCUS) Non-Current Debt (2024)

Updated

Analysis

Arcus Biosciences (RCUS) Non-Current Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,134.96 Bn 1,103.55 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 616.51 Bn 535.04 Bn 17.26 Bn 37.34 Bn
3 AbbVie 501.10 Bn 474.21 Bn 12.70 Bn 62.48 Bn
4 Merck 367.09 Bn 321.47 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 298.10 Bn 262.09 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.72 Bn 235.40 Bn 12.86 Bn 23.68 Bn
7 Amgen 235.73 Bn 191.13 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 190.64 Bn 164.84 Bn 6.22 Bn 23.83 Bn
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn 60.50 Bn
10 Arcus Biosciences 2.60 Bn -735.82 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 47.00 Mn
API Access

Arcus Biosciences Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=RCUS&period=max&api_key=YOUR_API_KEY